Asciminib Offers Additional Tool to Treat CML-CP

News
Video

Talha Badar, MBBS, MD, discussed how results from the phase 3 ASCEMBL study of asciminib will impact clinical practice in treating chronic myeloid leukemia in chronic phase.

As part of CancerNetwork’s Face-Off video series, Talha Badar, MBBS, MD, assistant professor of oncology, Mayo Clinic, discussed how clinical practice may change following the readout of the phase 3 ASCEMBL study (NCT03106779).

The trial compared treatment with asciminib (Scemblix) versus bosutinib (Bosulif) in patients with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs).

Badar: So, I will answer this question in context to the other abstract which was presented as an oral abstract [at the 2022 American Society of Hematology Annual Meeting and Exposition] by Dr. Jubour, evaluating the outcome of patients who had progressed, CML patients with chronic phase who progressed on second-line TKI. At [The University of Texas] MD Anderson [Cancer Center], a large pool of CML patients with chronic phase and evaluated outcomes and variables that predict response in these patients.

So what they found out, which is notable and somehow related to the study, patients having said progression on secondary TKIs, like bosutinib, erlotinib [Terceva], defactinib, and if they are switched to ponatinib-based therapy that tends to have a better outcome. So in patients who are progressing on second-generation TKI, it made more sense to use the third generation or novelty TKI then switching from 1 second-generation TKI to another second-generation TKI.

So let's say if you're a patient who had a prior progression on a second-generation TKI, it doesn’t make sense to put them into bosutinib, you would like to put them on a better TKI therapy. In that scenario on that paper, it was ponatinib. I assume. extrapolating the data, we have the activity and efficacy of anatomy and patient TC15i I in general, in 2 prior lines of TKI therapy. In clinics, you come across a patient who had progression on second-generation TKI or ponatinib in that scenario. Ponatinib is challenging, with some adverse effect profile in patients who have cardiovascular disease, which is not better control. And there are issues with tolerance and toxicity. So in that scenario, if you have to choose asciminib would be ideal in terms of having that response.

The caveat to this is there is no head-to-head trial with a similar when printed and we won't be able to have 1 in that space. But it's still something to consider and some tool available to manage and cater to those patients.

Transcription edited for clarity.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.